InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026

InflaRx (IFRX) will present pre-clinical izicopan data in a late-breaking poster session at Kidney Week on October 22, 2026.

Rhea-AI Summary

InflaRx (IFRX) will present pre-clinical izicopan data in a late-breaking poster session at Kidney Week on October 22, 2026. The poster concerns izicopan’s therapeutic potential in kidney disease models. The session runs from 10:00 AM to 12:00 PM during the American Society of Nephrology’s meeting in Denver, Colorado, October 21–25.

Izicopan is an oral inhibitor of C5aR, a receptor involved in inflammation. InflaRx plans to develop it for ANCA-associated vasculitis and additional renal indications.

Key Figures

Single-dose range: 3 mg to 240 mg Multiple-dose regimens: 30 mg once per day to 90 mg twice per day for 14 days C5a-induced neutrophil activation blockade: ≥90%

Single-dose range

3 mg to 240 mg

First-in-human study

Multiple-dose regimens

30 mg once per day to 90 mg twice per day for 14 days

First-in-human study

C5a-induced neutrophil activation blockade

≥90%

Achieved over the 14-day dosing period

Key Terms

cyp3a4, pharmacokinetic / pharmacodynamic, anca-associated vasculitis, human liver microsomes

4 terms

cyp3a4 medical

"time-dependent inhibition of cytochrome P450 3A4 (CYP3A4)"

CYP3A4 is a liver enzyme that acts like a chemical filter, breaking down a large share of prescription drugs and other substances in the body. Investors pay attention because how a drug is processed by CYP3A4 affects dosing, side effects, drug interactions, clinical trial outcomes and regulatory approvals, all of which can significantly influence a drug’s safety profile, market potential and revenue prospects.

pharmacokinetic / pharmacodynamic medical

"Pharmacokinetic / pharmacodynamic data support"

Pharmacokinetics (PK) describes how a drug moves through the body — how it is absorbed, distributed, broken down and removed — while pharmacodynamics (PD) describes what the drug does to the body and how strong or long the effect is. Together they tell investors whether a medicine can reach the right level in the body safely and produce a reliable benefit, similar to knowing a car’s fuel efficiency (PK) and how well it accelerates (PD), which affect performance, safety and commercial potential.

anca-associated vasculitis medical

"development of izicopan in ANCA-associated vasculitis (AAV)"

A condition in which the immune system mistakenly attacks and inflames blood vessels, driven by specific antibodies called ANCAs; this can reduce blood flow and damage organs such as kidneys, lungs and nerves, similar to “friendly fire” damaging the body’s plumbing. Investors should care because its rarity, severity and complex treatment needs drive clinical trial activity, regulatory scrutiny, pricing, and potential market opportunities or risks for therapies and diagnostics.

human liver microsomes technical

"favorable reactive metabolite profile in human liver microsomes"

Human liver microsomes are a laboratory preparation made by breaking up donated human liver tissue and isolating the small membrane fragments (microsomes) that contain drug‑metabolizing enzymes, especially cytochrome P450s and some UDP‑glucuronosyltransferases. They are used in in vitro tests to measure how quickly a compound is metabolized, to identify which enzymes metabolize it, and to screen for potential drug–drug interaction risk; because microsomes lack intact cells, blood flow, and some other enzymes and transporters, their results must be scaled or complemented with other data to predict whole‑body clearance accurately.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Jena, Germany, Oct. 02, 2026 (GLOBE NEWSWIRE) --  InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company has been selected for a late-breaking poster session at the American Society of Nephrology’s Kidney Week 2026, taking place in Denver, Colorado, USA, October 21 - 25.

Kidney Week 2026 Late-Breaking Poster Details

Title: Izicopan, a Second-Generation Oral C5a Receptor 1 (C5aR1) Antagonist, Demonstrates Promising Therapeutic Potential in Kidney Disease Models.

Poster Session
Session Title: Late-Breaking Research Posters [LB-PO]
Session Date, Time: October 22, 2026 from 10:00 AM to 12:00 PM

About izicopan
Izicopan is an orally administered, small molecule inhibitor of the C5a receptor (C5aR) that has shown anti-inflammatory therapeutic effects in several pre-clinical disease models and in human studies. InflaRx is planning for development of izicopan in ANCA-associated vasculitis (AAV) and additional renal indications.
In contrast to the marketed C5aR inhibitor, in vitro experiments demonstrated that izicopan does not exhibit time-dependent inhibition of cytochrome P450 3A4 (CYP3A4), which plays an important role in the metabolism of a variety of metabolites and drugs, including glucocorticoids. Izicopan has also demonstrated a favorable reactive metabolite profile in human liver microsomes. Reported results from a first-in-human study demonstrated that izicopan was well tolerated in treated subjects and exhibited no safety signals of concern in single doses ranging from 3 mg to 240 mg or multiple doses ranging from 30 mg once per day to 90 mg twice per day for 14 days. Pharmacokinetic / pharmacodynamic data support the best-in-class potential of izicopan, with a ≥90% blockade of C5a-induced neutrophil activation achieved over the 14-day dosing period. Topline Phase 2a data further support the safety profile of izicopan, with no reported safety signals of concern. In patients with hidradenitis suppurativa, over 4 weeks of therapy, izicopan provided rapid and clinically meaningful reductions in abscesses and nodules and draining tunnels, robust HiSCR responses that continued to deepen four weeks after the treatment period, and substantial reductions in patient-reported pain scores, overall demonstrating the potential for biologic-like efficacy. In chronic spontaneous urticaria, InflaRx observed substantial reductions in the 7-day Urticaria Activity Score (UAS7) broadly across patients and particularly in those with severe disease, as well as improved disease control as measured by the Urticaria Control Test (UCT7).

About InflaRx
InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor, C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx‘s lead program is izicopan, an orally administered small molecule inhibitor of C5a-induced signaling via the C5a receptor, which has shown promising PK/PD characteristics as well as therapeutic potential in Phase 1 and Phase 2a clinical studies. The Company is developing izicopan for the treatment of ANCA-associated vasculitis and additional renal diseases. InflaRx also has developed vilobelimab, a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies.

InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.de. Follow InflaRx on LinkedIn. InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, InflaRx).

Contacts:

InflaRx N.V.	MC Services AG
Jan Medina, CFA Vice President, Head of Investor Relations Email: IR@inflarx.de	Katja Arnold, Laurie Doyle, Dr. Regina Lutz Email: inflarx@mc-services.eu Europe: +49 89-210 2280 U.S.: +1-339-832-0752

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue,” among others. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses, current expectations and the risks, uncertainties and other factors described under the heading “Risk Factors” and “Cautionary statement regarding forward looking statements” in our periodic filings with the SEC. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.